万邦医药
(301520)
| 流通市值：8.02亿 | | | 总市值：32.07亿 |
| 流通股本：1666.67万 | | | 总股本：6666.67万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 90,172,342.02 | 341,806,532.85 | 240,653,628.05 | 164,992,422.62 |
| 营业收入 | 90,172,342.02 | 341,806,532.85 | 240,653,628.05 | 164,992,422.62 |
| 二、营业总成本 | 65,349,751.67 | 230,811,694.31 | 159,525,538.79 | 104,625,082.21 |
| 营业成本 | 47,825,532.49 | 174,533,801.52 | 117,126,839.03 | 79,685,371.46 |
| 税金及附加 | 369,055.88 | 1,160,781.71 | 769,572.33 | 403,504.74 |
| 销售费用 | 939,770.05 | 4,536,071.16 | 3,787,945.46 | 3,112,964.24 |
| 管理费用 | 6,809,525.67 | 20,674,727.06 | 14,287,994.68 | 8,909,825.66 |
| 研发费用 | 10,738,916.39 | 34,521,095.42 | 23,892,759.21 | 12,690,925.68 |
| 财务费用 | -1,333,048.81 | -4,614,782.56 | -339,571.92 | -177,509.57 |
| 其中:利息费用 | 0 | 115.79 | 115.79 | 115.79 |
| 其中:利息收入 | 1,338,763.35 | 4,630,628.63 | 350,405.19 | 186,278.04 |
| 加:公允价值变动收益 | 6,879,458.32 | 3,786,249.98 | 858,249.99 | - |
| 加:投资收益 | 679,300.01 | 2,433,044.4 | 2,007,260.74 | 1,736,031.64 |
| 资产减值损失(新) | -448,901.3 | -1,454,080.3 | -1,570,905.04 | -966,121.01 |
| 信用减值损失(新) | -103,996.54 | -2,653,135.76 | -1,145,390.45 | -1,470,250.1 |
| 其他收益 | 299,034.55 | 5,899,257.48 | 4,297,585.21 | 813,600.08 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 32,127,485.39 | 119,006,174.34 | 85,574,889.71 | 60,480,601.02 |
| 加:营业外收入 | 291,700 | 757,586.33 | 468,573.87 | 320,631.49 |
| 减:营业外支出 | 43,418.62 | 118,852.39 | 100,109 | 100,000 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 32,375,766.77 | 119,644,908.28 | 85,943,354.58 | 60,701,232.51 |
| 减:所得税费用 | 2,688,682.51 | 11,553,058.97 | 8,631,890.05 | 6,880,674.03 |
| 六、净利润 | 29,687,084.26 | 108,091,849.31 | 77,311,464.53 | 53,820,558.48 |
| 持续经营净利润 | 29,687,084.26 | 108,091,849.31 | 77,311,464.53 | 53,820,558.48 |
| 归属于母公司股东的净利润 | 29,687,084.26 | 108,091,849.31 | 77,311,464.53 | 53,820,558.48 |
| (一)基本每股收益 | 0.45 | 2 | 1.55 | 1.08 |
| (二)稀释每股收益 | 0.45 | 2 | 1.55 | - |
| 八、其他综合收益 | - | - | 0 | - |
| 归属于母公司股东的其他综合收益 | - | - | 0 | - |
| 九、综合收益总额 | 29,687,084.26 | 108,091,849.31 | 77,311,464.53 | 53,820,558.48 |
| 归属于母公司股东的综合收益总额 | 29,687,084.26 | 108,091,849.31 | 77,311,464.53 | 53,820,558.48 |
| 归属于少数股东的综合收益总额 | - | - | 0 | - |
| 公告日期 | 2024-04-20 | 2024-04-20 | 2023-10-25 | 2023-09-05 |
| 审计意见(境内) | | 标准无保留意见 | | |